论文部分内容阅读
目的:探讨尿激酶联合复方丹参及川芎嗪注射液治疗急性心肌梗死患者的临床疗效及安全性。方法:选取80例急性心肌梗死患者作为研究对象,随机分为对照组与观察组各40例,两组患者均给予常规基础治疗,对照组采用尿激酶治疗,观察组采用尿激酶联合复方丹参及川芎嗪注射液静脉滴注,观察两组患者临床疗效。结果:经治疗,溶栓后两组患者血管再通率、死亡率、并发症发生率比较差异无统计学意义(P>0.05),观察组再灌注心律失常发生率明显低于对照组(P<0.05),观察组存活患者CKMB降至正常所需时间明显短于对照组(P<0.05)。结论:采用尿激酶联合复方丹参及川芎嗪注射液治疗急性心肌梗死疗效确切,可抑制再灌注心律失常的发生率,减轻心肌损害,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of urokinase plus compound salvia miltiorrhiza and ligustrazine injection in patients with acute myocardial infarction. Methods: Eighty patients with acute myocardial infarction were selected as study subjects and randomly divided into control group and observation group of 40 cases. Both groups were given routine basic treatment, the control group was treated with urokinase, the observation group was treated with urokinase combined with compound Salvia miltiorrhiza and Ligustrazine injection intravenous infusion, the clinical efficacy of two groups were observed. Results: There was no significant difference in the rates of recanalization, mortality and complication between the two groups after treatment (P> 0.05). The incidence of reperfusion arrhythmia in the observation group was significantly lower than that in the control group (P <0.05). The time required for CKMB to be normal in survival patients in the observation group was significantly shorter than that in the control group (P <0.05). Conclusion: Urokinase combined with compound Salvia miltiorrhiza and ligustrazine injection in the treatment of acute myocardial infarction is effective and can inhibit the incidence of reperfusion arrhythmia, reduce myocardial damage, it is worthy of clinical promotion and application.